LCM
MCID: MNT001
MIFTS: 72

Mantle Cell Lymphoma (LCM) malady

Categories: Rare diseases, Cancer diseases, Blood diseases, Immune diseases

Aliases & Classifications for Mantle Cell Lymphoma

About this section
Sources:
11Disease Ontology, 12diseasecard, 13DISEASES, 27GTR, 30ICD10, 31ICD10 via Orphanet, 35LifeMap Discovery®, 39MeSH, 40MESH via Orphanet, 48NIH Rare Diseases, 50Novoseek, 54Orphanet, 68UMLS
See all MalaCards sources

Aliases & Descriptions for Mantle Cell Lymphoma:

Name: Mantle Cell Lymphoma 35 11 48 54 13
Lymphoma, Mantle Cell 48 27 12
Malignant Lymphoma, Lymphocytic, Intermediate Differentiation, Diffuse 68
Malignant Lymphoma - Lymphocytic, Intermediate Differentiation 68
Lymphoma, Mantle-Cell 39
 
Lymphoma Mantle-Cell 50
Mantle Zone Lymphoma 54
Mcl 54
Lcm 54

Characteristics:

Orphanet epidemiological data:

54
mantle cell lymphoma:
Inheritance: Multigenic/multifactorial,Not applicable; Prevalence: 1-9/1000000 (United States),1-9/100000 (Europe),1-9/100000 (France); Age of onset: Adult; Age of death: adult

Classifications:



External Ids:

Disease Ontology11 DOID:0050746
MeSH39 D020522
Orphanet54 ORPHA52416
MESH via Orphanet40 D020522
ICD10 via Orphanet31 C83.1
ICD1030 C83.1

Summaries for Mantle Cell Lymphoma

About this section
NIH Rare Diseases:48 Mantle cell lymphoma (mcl) belongs to a group of diseases known as non-hodgkin’s lymphomas (nhl). nhl's are cancers that affect the the lymphatic system (part of the immune system). in mcl, there are cancerous b-cells (a type of immune system cell). the cancerous b-cells are within a region of the lymph node known as the mantle zone. although mcls are slow-growing cancers, the cancer is usually widespread by the time it is diagnosed. in these situations, treatment must be intensive since mcl can become life threatening within a short period of time. mcl accounts for 6% of all nhl's and is mostly found in males during their early 60s. last updated: 4/27/2016

MalaCards based summary: Mantle Cell Lymphoma, also known as lymphoma, mantle cell, is related to lymphoma and leukemia, and has symptoms including Array, Array and Array. An important gene associated with Mantle Cell Lymphoma is ATM (ATM Serine/Threonine Kinase), and among its related pathways are ATM Pathway and p53 pathway (Pathway Interaction Database). Affiliated tissues include b cells, bone and bone marrow, and related mouse phenotypes are Increased viability with MLN4924 (a NAE inhibitor) and Increased cell death HMECs cells.

Disease Ontology:11 A B-cell lymphocytic neoplasm due to CD5 positive antigen-naive pregerminal center B-cell within the mantle zone that surrounds normal germinal center follicles.

Wikipedia:71 Mantle cell lymphoma (MCL) is a type of non-Hodgkin\'s lymphoma (NHL), comprising about 6% of NHL cases.... more...

Related Diseases for Mantle Cell Lymphoma

About this section

Diseases related to Mantle Cell Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 175)
idRelated DiseaseScoreTop Affiliating Genes
1lymphoma11.2
2leukemia10.4
3male infertility10.4BCL2, CCND1
4villoglandular endometrial endometrioid adenocarcinoma10.4ATM, CCND1, TP53
5parotitis10.4CCND1, CD5, SOX11
6uterine ligament endometrioid adenocarcinoma10.4CCND1, CD5, SOX11
7cervical verrucous carcinoma10.4CCND1, MDM2, TP53
8b-cell lymphomas10.4
9hemorrhagic proctocolitis10.4CCND1, MTOR, MYC
10intraorbital meningioma10.4ATM, MDM2, TP53
11his bundle tachycardia10.4BCL2, CCND1, TP53
12spastic paraplegia 110.4BCL2, MDM2, TP53
13chronic lymphocytic leukemia10.4
14rommen mueller sybert syndrome10.3MDM2, TP53
15statin toxicity10.3BCL2, CCND1, TP53
16trigeminal nerve neoplasm10.3CD5, MME
17seminal vesicle chronic gonorrhea10.3ATM, CCND1, CD5, MYC
18cecum adenoma10.3BCL2, CCND1, MDM2, TP53
19duodenal ulcer10.3ATM, CD5, MYC, TP53
20nasopharyngeal carcinoma10.3ATM, BCL2, MDM2, TP53
21cleft palate cardiac defect ectrodactyly10.3BCL2, CCND1, TP53
22vaginal adenosarcoma10.3BCL2, MME, TP53
23nevoid hypermelanosis, linear and whorled10.3BCL2, CCND1, MYC, TP53
24progressive external ophthalmoplegia with mitochondrial dna deletions, autosomal dominant 310.3MCL1, MDM2, MYC, TP53
25placenta praevia10.3CCND1, MDM2, MYC, TP53
26pyloric antrum cancer10.3BCL2, BCL6, TP53
27progesterone-receptor negative breast cancer10.3CCND1, MTOR, TP53
28spinal cord intramedullary teratoma10.3BCL6, CD5, TP53
29ichthyosis, congenital, autosomal recessive 1010.3BCL2, BCL6, IGH
30rubella panencephalitis10.3BCL2, BCL6
31maxillary sinus cholesteatoma10.3BMI1, CCND1, TP53
32thoracic outlet syndrome10.3BCL2, CCND1, MDM2, MYC, TP53
33barnicoat baraitser syndrome10.3CD19, CD5, MYC, TP53
34glucose-6-phosphate translocase deficiency10.3MDM2, MTOR, MYC, TP53
35theileriasis10.3CCND1, CD5, MYC
36post-surgical hypoinsulinemia10.3CCND1, CCND3, MDM2, MYC, TP53
37adult astrocytic tumour10.3MDM2, MTOR, MYC, TP53
38glucosephosphate isomerase deficiency10.3BCL2, MDM2, MTOR, TP53
39small cell cancer of the lung, somatic10.3CCND1, CCND2, CCND3, MDM2, TP53
40degenerative myopia10.3CD19, CD5, MME
41malignant pleural solitary fibrous tumor10.3CCND1, MME, MYC, TP53
42hodgkin lymphoma10.2
43penile disease10.2BCL6, CD19, CD5
44lip cancer10.2BCL2, BCL6, CCND3
45arteriosclerosis10.2BTK, CD19, CD5
46teebi naguib al awadi syndrome10.2BCL6, IGH, MME
47extraocular retinoblastoma10.2CCND1, CCND2, CCND3, MDM2, MYC, TP53
48integumentary system benign neoplasm10.2CCND1, CCND2, CCND3, MDM2, MYC, TP53
49basal ganglia disease10.2BCL6, CD19, CD5
50childhood brain stem glioma10.2ATM, CCND1, CD5, MME, SOX11, TP53

Graphical network of the top 20 diseases related to Mantle Cell Lymphoma:



Diseases related to mantle cell lymphoma

Symptoms & Phenotypes for Mantle Cell Lymphoma

About this section

Human phenotypes related to Mantle Cell Lymphoma:

 54 64 (show all 9)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 splenomegaly64 54 Frequent (79-30%) HP:0001744
2 weight loss64 54 Frequent (79-30%) HP:0001824
3 anorexia64 54 Frequent (79-30%) HP:0002039
4 lymphadenopathy64 54 Very frequent (99-80%) HP:0002716
5 abnormality of bone marrow cell morphology64 54 Frequent (79-30%) HP:0005561
6 abnormality of the gastrointestinal tract64 54 Occasional (29-5%) HP:0011024
7 fatigue64 54 Frequent (79-30%) HP:0012378
8 fever64 54 Frequent (79-30%) HP:0001945
9 b-cell lymphoma64 54 Very frequent (99-80%) HP:0012191

GenomeRNAi Phenotypes related to Mantle Cell Lymphoma according to GeneCards Suite gene sharing:

26
idDescriptionGenomeRNAi Source AccessionScoreTop Affiliating Genes
1GR00250-A-310.1ATM, BCL2, MCL1, MDM2, PMAIP1, TP53
2GR00103-A-010.0BCL6, BMI1, CCND2, MDM2, MYC, TP53
3GR00250-A-19.8ATM, BCL2, BTK, CCND1, MCL1, MYC

MGI Mouse Phenotypes related to Mantle Cell Lymphoma according to GeneCards Suite gene sharing:

41 (show all 17)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053809.7ATM, EZH2, MCL1, MDM2, MTOR, MYC
2MP:00053899.6ATM, BCL2, BCL6, CCND1, CCND2, MCL1
3MP:00020069.5ATM, BCL2, BTK, CCND1, CCND3, CD19
4MP:00053819.4BCL2, BTK, CCND1, CD19, MDM2, MYC
5MP:00053869.1ATM, BCL2, CCND1, CCND2, CCND3, CD19
6MP:00053708.8BCL6, CCND2, CCND3, CD19, MDM2, MME
7MP:00028738.8BCL6, CCND1, CCND3, CD19, CD5, EZH2
8MP:00053848.8ATM, BCL2, BCL6, BTK, CCND1, CD19
9MP:00036318.8ATM, BCL2, CCND1, CCND2, CD19, CD5
10MP:00053788.7ATM, BCL2, BCL6, BTK, CCND1, CCND3
11MP:00053858.6ATM, BCL2, BCL6, CCND1, CCND2, CCND3
12MP:00107718.6ATM, BCL2, BTK, CCND1, CD19, CD5
13MP:00053798.6ATM, BCL2, BCL6, CCND1, CCND2, CCND3
14MP:00053768.4ATM, BCL2, BCL6, BTK, CCND1, CCND2
15MP:00107688.4ATM, BCL2, BCL6, BTK, CCND1, CCND2
16MP:00053878.0ATM, BCL2, BCL6, BTK, CCND1, CCND2
17MP:00053977.9ATM, BCL2, BCL6, BTK, CCND1, CCND2

Drugs & Therapeutics for Mantle Cell Lymphoma

About this section

FDA approved drugs:

id Drug Name Active Ingredient(s)16 Company Approval Date
1
Imbruvica16 44 IBRUTINIB Pharmacyclics November of 2013/ February 2014
FDA Label: Imbruvica
Disease/s that Drug Treats:mantle cell lymphoma/chronic lymphocytic leukemia
Indications and Usage:16 IMBRUVICA is a kinase inhibitor indicated for the treatment of patients with: Mantle cell lymphoma (MCL) who have received at least one priortherapy (1.1).Accelerated approval was granted for this indication based on overallresponse rate. Continued approval for this indication may be contingentupon verification of clinical benefit in confirmatory trials. Chronic lymphocytic leukemia (CLL) who have received at least oneprior therapy (1.2). Chronic lymphocytic leukemia with 17p deletion (1.3). Waldenström’s macroglobulinemia (WM) (1.4).
DrugBank Targets:14 1. Tyrosine-protein kinase BTK
Mechanism of Action:16 
Target: Bruton's tyrosine kinase (Btk)
Action: selective inhibitor
FDA: Ibrutinib is a small-molecule inhibitor of BTK. Ibrutinib forms a covalent bond with a cysteineresidue in the BTK active site, leading to inhibition of BTK enzymatic activity. BTK is asignaling molecule of the B-cell antigen receptor (BCR) and cytokine receptor pathways. BTK’srole in signaling through the B-cell surface receptors results in activation of pathways necessaryfor B-cell trafficking, chemotaxis, and adhesion. Nonclinical studies show that ibrutinib inhibitsmalignant B-cell proliferation and survival in vivo as well as cell migration and substrateadhesion in vitro.
2
Revlimid16 44 LENALIDOMIDE Celgene June 2013
FDA Label: Revlimid
Disease/s that Drug Treats:mantle cell lymphoma
Indications and Usage:16 REVLIMID is a thalidomide analogue indicated for the treatment of patientswith: Multiple myeloma (MM), in combination with dexamethasone (1.1). Transfusion-dependent anemia due to low- or intermediate-1-riskmyelodysplastic syndromes (MDS) associated with a deletion 5qabnormality with or without additional cytogenetic abnormalities (1.2). Mantle cell lymphoma (MCL) whose disease has relapsed or progressedafter two prior therapies, one of which included bortezomib (1.3).Limitations of Use: REVLIMID is not indicated and is not recommended for the treatmentof patients with chronic lymphocytic leukemia (CLL) outside ofcontrolled clinical trials (1.4).
DrugBank Targets:14 1. Protein cereblon;2. Tumor necrosis factor ligand superfamily member 11;3. Cadherin-5;4. Prostaglandin G/H synthase 2
Mechanism of Action:16 
Target: T cells and natural killer cells/ pro-inflammatory cytokines by monocytes
Action: activator/inhibitor
FDA: Lenalidomide is an analogue of thalidomide with immunomodulatory, antiangiogenic, and antineoplastic properties. Lenalidomide inhibitsproliferation and induces apoptosis of certain hematopoietic tumor cells including multiple myeloma, mantle cell lymphoma, and del (5q)myelodysplastic syndromes in vitro. Lenalidomide causes a delay in tumor growth in some in vivo nonclinical hematopoietic tumor modelsincluding multiple myeloma. Immunomodulatory properties of lenalidomide include activation of T cells and natural killer (NK) cells, increasednumbers of NKT cells, and inhibition of pro-inflammatory cytokines (e.g., TNF-α and IL-6) by monocytes. In multiple myeloma cells, thecombination of lenalidomide and dexamethasone synergizes the inhibition of cell proliferation and the induction of apoptosis.
3
Velcade16 44 BORTEZOMIB Millennium Pharmaceuticals May 2003
FDA Label: Velcade
Disease/s that Drug Treats:Multiple Myeloma
Indications and Usage:16 VELCADE is a proteasome inhibitor indicated for: treatment of patients with multiple myeloma (1.1) treatment of patients with mantle cell lymphoma (1.2)
DrugBank Targets:14 1. 26S proteasome non-ATPase regulatory subunit 2;2. 26S proteasome non-ATPase regulatory subunit 1;3. Proteasome subunit beta type-1;4. Proteasome subunit beta type-5;5. Proteasome subunit beta type-2
Mechanism of Action:16 
Target: 26S proteasome
Action: reversible inhibitor of chymotrypsin-like activity
FDA: Bortezomib is a reversible inhibitor of the chymotrypsin-like activity of the 26S proteasome in mammaliancells. The 26S proteasome is a large protein complex that degrades ubiquitinated proteins. The ubiquitinproteasomepathway plays an essential role in regulating the intracellular concentration of specific proteins,thereby maintaining homeostasis within cells. Inhibition of the 26S proteasome prevents this targetedproteolysis, which can affect multiple signaling cascades within the cell. This disruption of normal homeostaticmechanisms can lead to cell death. Experiments have demonstrated that bortezomib is cytotoxic to a variety ofcancer cell types in vitro. Bortezomib causes a delay in tumor growth in vivo in nonclinical tumor models,including multiple myeloma.

Drugs for Mantle Cell Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 495)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
rituximabapprovedPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 11692174722-31-710201696
Synonyms:
AntiCD20
IDEC-102
IDEC-C2B8
 
Ig gamma-1 chain C region
MabThera
Mabthera
Rituxan
rituximab
2
Cytarabineapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 11117147-94-46253
Synonyms:
(beta-D-Arabinofuranosyl)cytosine
(beta-D-arabinofuranosyl)cytosine
1-.beta.-D-arabinofuranosyl-cytosine
1-Arabinofuranosylcytosine
1-beta -D-Arabinofaranosylcytosine
1-beta -D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone
1-beta -D-Arabinofuranosylcytosine
1-beta-D-Arabinofaranosylcytosine
1-beta-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone
1-beta-D-Arabinofuranosyl-Cytosine
1-beta-D-Arabinofuranosylcytosine
1-beta-D-Arabinofuranosylcytosine, Cytosine Arabinoside
1-beta-D-Arabinosyl-Cytosine
1-beta-D-Arabinosylcytosine
147-94-4
1beta -Arabinofuranasylcytosine
1beta -D-Arabinofuranosylcytosine
1beta -D-Arabinosylcytosine
1beta-Arabinofuranasylcytosine
1beta-D-Arabinofuranosylcytosine
1beta-D-Arabinosylcytosine
2(1H)-Pyrimidinone, 4-amino-1- -D-arabinofuranosyl- [CAS]
2(1H)-Pyrimidinone, 4-amino-1- -D-arabinofuranosyl
30399_FLUKA
4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin
4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin [Czech]
4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidine
4-Amino-1-b-D-arabinofuranosyl-2-(1H)-pyrimidinone
4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinon
4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinon [Czech]
4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone
4-amino-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
4-amino-1-beta-D-arabinofuranosylpyrimidin-2(1H)-one
69-74-9 (hydrochloride)
AC-1075
AC1L1M4F
AC1Q52OJ
AI3-52329
AR3
Alexan
Ara-C
Ara-C, Cytosine Arabinoside, Cytosar-U, Cytarabine
Ara-Cytidine
AraC
Arabinocytidine
Arabinofuranosylcytosine
Arabinosyl Cytosine
Arabinosylcytosine
Arabitin
Aracytidine
Aracytin
Aracytine
Arafcyt
BIDD:GT0371
BIDD:PXR0139
BTB15125
Beta-cytosine arabinoside
C02961
C1768_SIGMA
C2035
C9H13N3O5
CCRIS 913
CHEBI:28680
CHEMBL803
CHX 3311
CID6253
CPD000449317
CYTARABINE (SEE ALSO CYTARABINE HYDROCHLORIDE 69-74-9)
Citarabina
Citarabina [INN-Spanish]
Cytarabin
Cytarabina
Cytarabine (JP15/USP/INN)
Cytarabine [USAN:INN:BAN:JAN]
 
Cytarabine liposome injection
Cytarabinoside
Cytarabinum
Cytarabinum [INN-Latin]
Cytarbel
Cytonal
Cytosar
Cytosar-U
Cytosine 1-beta-D-arabinofuranoside
Cytosine arabinofuranoside
Cytosine arabinose
Cytosine arabinoside
Cytosine arabinoside (VAN)
Cytosine beta-D-arabinofuranoside
Cytosine beta-D-arabinofuranoside hydrochloride
Cytosine beta-D-arabinoside
Cytosine, beta -D-arabinoside
Cytosine, beta-D-arabinoside
Cytosine-1-beta-D-arabinofuranoside
Cytosine-1-beta-D-arabinofuranoside hydrochloride
Cytosine-beta -D-arabinofuranoside
Cytosine-beta -arabinoside
Cytosine-beta-D-arabinofuranoside
Cytosine-beta-arabinoside
Cytosinearabinoside
D00168
DB00987
DepoCyte
Depocyt
Depocyt (TN)
Depocyt (liposomal)
Depocyte
EINECS 205-705-9
Erpalfa
FT-0082880
HMS2051K19
HMS2090A18
HSDB 3049
Intrathecal (injected into the spinal fluid) DepoCyt
Intrathecal cytarabine (also known as ara-C)
Iretin
LS-860
Lopac0_000316
MLS000758310
MLS001066340
MolPort-001-792-509
NCGC00093356-03
NCGC00093356-04
NCGC00093356-05
NCI-C04728
NSC 287459
NSC287459
S1648_Selleck
SAM001247012
SMR000449317
SR-01000075773-3
Spongocytidine
TL8001048
Tarabine
U 19920A
U-19,920
U-19920
UNII-04079A1RDZ
Udicil
ZINC03795098
beta -D-arabinosylcytosine
beta -arabinosylcytosine
beta -cytosine arabinoside
beta-Ara C
beta-Ara c
beta-Arabinosylcytosine
beta-Cytosine arabinoside
beta-D-Arabinosylcytosine
cytarabine
cytarabine liposome injection
cytosine-β-D-arabinofuranoside
3
Prednisoneapproved, vet_approvedPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 1139853-03-25865
Synonyms:
(1S,2R,10S,11S,14R,15S)-14-hydroxy-14-(2-hydroxyacetyl)-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-diene-5,17-dione
(8S,9S,10R,13S,14S,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,9,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,11-dione
(8xi,9xi,14xi)-17,21-dihydroxypregna-1,4-diene-3,11,20-trione
.delta. E
.delta.(sup1)-Cortisone
.delta.-Cortelan
.delta.-Cortisone
.delta.-Cortone
.delta.-E
.delta.1-Cortisone
.delta.1-Dehydrocortisone
.delta.sone
1,2-Dehydrocortisone
1,4-Pregnadiene-17-alpha,21-diol-3,11,20-trione
1,4-Pregnadiene-17.alpha.,21-diol-3,11,20-trione
1,4-Pregnadiene-17alpha,21-diol-3,11,20-trione
1-Cortisone
1-Dehydrocortisone
17,21-Dihydroxypregna-1,4-diene-3,11,20-trione
17alpha,21-Dihydroxy-1,4-pregnadiene-3,11,20-trione
53-03-2
68-59-7
81552_FLUKA
AC-11112
AC1L1LB2
AC1Q29EZ
ACon0_000082
ACon1_000297
AI3-52939
Adasone
Ancortone
Apo-Prednisone
Apo-prednisone
BPBio1_000323
BRD-K85883481-001-04-2
BSPBio_000293
Betapar
Bicortone
Bio-0649
C07370
C21H26O5
CCRIS 2646
CHEBI:8382
CHEMBL635
CID5865
CPD001227202
Cartancyl
Colisone
Cortan
Cortancyl
Cortidelt
Cotone
DB00635
Dacorten
Dacortin
Decortancyl
Decortin
Decortisyl
Dehydrocortisone
Dekortin
Delcortin
Dellacort
Dellacort A
Delta Cortelan
Delta E
Delta E.
Delta-Cortelan
Delta-Dome
Delta-cortelan
Delta-cortisone
Delta-cortone
Delta-dome
Deltacortene
Deltacortisone
Deltacortone
Deltasone
Deltasone, Liquid Pred, Orasone, Adasone, Deltacortisone,Prednisone
Deltison
Deltisona
Deltisone
Deltra
Di-Adreson
Diadreson
EINECS 200-160-3
Econosone
Encorton
Encortone
Enkortolon
Enkorton
Fernisone
Fiasone
HMS1568O15
HMS2090J13
HSDB 3168
Hostacortin
In-Sone
Incocortyl
 
Juvason
Kortancyl
LMST02030180
LS-1325
Liquid Pred
Lisacort
Lodotra
MEGxm0_000443
MLS001061265
MLS001304073
MLS001335907
MLS001335908
MLS002154191
MLS002207083
Me-Korti
Metacortandracin
Meticorten
Meticorten (Veterinary)
Metrevet (Veterinary)
MolPort-001-740-041
NCGC00090766-01
NCGC00090766-02
NCGC00090766-03
NCI-C04897
NCI60_000008
NSC 10023
NSC10023
Nisona
Nizon
Novoprednisone
Nurison
Orasone
Origen Prednisone
P1276
P6254_SIGMA
PRD
Panafcort
Panasol
Paracort
Parmenison
Pehacort
Precort
Predeltin
Prednicen-M
Prednicorm
Prednicort
Prednicot
Prednidib
Prednilonga
Prednison
Prednisona
Prednisona [INN-Spanish]
Prednisone
Prednisone Intensol
Prednisone [INN:BAN]
Prednisonum
Prednisonum [INN-Latin]
Prednitone
Prednizon
Prednovister
Presone
Prestwick0_000077
Prestwick1_000077
Prestwick2_000077
Prestwick3_000077
Prestwick_405
Pronison
Pronisone
Rectodelt
Retrocortine
S1622_Selleck
SAM002264641
SK-Prednisone
SMR000718760
SMR001227202
SPBio_002214
Servisone
Sone
Sterapred
Supercortil
U 6020
UNII-VB0R961HZT
Ultracorten
Ultracortene
WLN: L E5 B666 CV OV AHTTT&J A1 E1 FV1Q FQ
Winpred
Wojtab
ZINC03875357
Zenadrid
Zenadrid (veterinary)
Zenadrid [veterinary]
delta cortelan
delta(sup 1)-Cortisone
delta(sup 1)-Dehydrocortisone
delta-1-Cortisone
delta-1-Dehydrocortisone
delta-Cortisone
delta-Cortone
4
CisplatinapprovedPhase 4, Phase 3, Phase 2, Phase 1277015663-27-184093, 441203, 2767
Synonyms:
(SP-4-1)-diamminedichloridoplatinum
(SP-4-1)-diamminedichloroplatinum
(SP-4-2)-diamminedichloridoplatinum
(SP-4-2)-diamminedichloroplatinum
Abiplatin
Biocisplatinum
Briplatin
CACP
CDDP
CHEBI:35852
CID441203
CPD0-1392
CPDC
CPDD
Carboquone
Cis Pt II
Cis-DDP
Cis-Diaminedichloroplatinum
Cis-Diamminedichloroplatinum
Cismaplat
Cisplatine
Cisplatino
Cisplatinum
Cisplatyl
Citoplationo
DB00515
DDP
DDPT
Diamminedichloroplatinum
 
EU-0100918
Lederplatin
Neoplatin
Peyrone's chloride
Peyrone's salt
Plastin
Platamine
Platiblastin
Platidiam
Platinex
Platinol
Platinol-AQ
Platinoxan
Platinum Ammine Chloride
Platinum Ammonium Chloride
Platinum Diamine Dichloride
Randa
Trans-DDP
Trans-Diaminedichloroplatinum
Trans-Diamminedichloroplatinum
Trans-Dichlorodiammine Platinum
Trans-Platinumdiammine Dichloride
cis-DDP
cis-Diamminedichloroplatinum
cis-Dichlorodiammineplatinum(II)
cis-[PtCl2(NH3)2]
cis-diamminedichloridoplatinum(II)
cis-diamminedichloroplatinum(II)
nchembio773-comp1
trans-diamminedichloridoplatinum(II)
5
EtoposideapprovedPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 1126933419-42-036462
Synonyms:
(-)-Etoposide
121471-01-0
136598-18-0
201594-04-9
33419-42-0
35317-32-9
4'-Demethyl-epipodophyllotoxin 9-[4,6-O-(R)-ethylidene-beta-D-glucopyranoside
4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-beta-D-glucopyranoside)
4'-Demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside)
4'-Demethylepipodophyllotoxin ethylidene-.beta.-D-glucoside
4'-O-Demethyl-1-O-(4,6-O-ethylidene-beta-D-glucopyranosyl)epipodophyllotoxin
4-Demethylepipodophyllotoxin beta-D-ethylideneglucoside
4-Demethylepipodophyllotoxin-.beta.-D-ethylideneglucoside
51854-34-3
76576-58-4
9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-D)-1,3-dioxol-6(5ah)-one
AB00438905
AC1L1FN8
AC1L1VT3
AC1L6246
AC1NR4OG
AC1O4WGG
AC1O7M1N
AC1Q47JJ
Ambap33419-42-0
BPBio1_000673
BRD-K37798499-001-02-5
BSPBio_000611
Bio1_000489
Bio1_000978
Bio1_001467
C01576
CCRIS 2392
CHEBI:4911
CHEBI:588795
CHEMBL44657
CID11758093
CID284997
CID3310
CID36462
CID5284558
CID6419930
CID6610299
CPD000112002
D00125
DB00773
DEMETHY-EPIPODOPHYLLOTOXIN,ETHYLIDENE GLUCOSIDE,
Demethyl Epipodophyllotoxin Ethylidine Glucoside
Demethyl-epiodophyllotoxin ethylidene glucoside
Demethylepipodophyllotoxin-beta-D-ethylideneglucoside
E0675
E1383_SIGMA
EINECS 251-509-1
EPE
EPEG
ETOP
Epipodophyllotoxin
Epipodophyllotoxin VP-16213
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-.beta.-D-glucopyranoside
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside (8CI)
Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-.beta.-D-glucopyranoside)
Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-beta-D-glucopyranoside)
Eposide
Eposin
 
Eposin, Vepesid, VP-16, Toposar, Etoposide
Etopol
Etopophos
Etopophos (phosphate salt)
Etoposid
Etoposide
Etoposide (JP15/USP/INN)
Etoposide (VP16)
Etoposide [USAN:INN:BAN:JAN]
Etoposido
Etoposido [INN-Spanish]
Etoposidum
Etoposidum [INN-Latin]
Etosid
HMS1569O13
HMS2052N05
HMS2089F14
HSDB 6517
I06-0248
KBioSS_002410
LS-1214
Lastet
MLS000049957
MLS001074951
MLS001424283
MLS002153463
MLS002207239
MLS002222184
MolPort-003-983-431
MolPort-004-905-001
MolPort-004-955-161
NCGC00025056-02
NChemBio.2007.10-comp19
NK 171
NSC 141540
NSC-141540
NSC141540
Prestwick0_000396
Prestwick1_000396
Prestwick2_000396
Prestwick3_000396
Prestwick_211
S1225_Selleck
SAM001246880
SMR000112002
SPBio_002532
ST056353
Toposar
UNII-6PLQ3CP4P3
VP 16
VP 16 (pharmaceutical)
VP 16-213
VP 16213
VP-16
VP-16-213
VePESID (TN)
VePesid
Vepesid
Vepesid J
Vepeside
ZINC03830818
ZINC03938684
Zuyeyidal
etoposide
nchembio.573-comp8
nchembio873-comp2
trans-Etoposide
6
Doxorubicinapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 1175123214-92-831703
Synonyms:
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside
(8S-cis)-10-((3-amino-2,3,6-Trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
111266-55-8
14-Hydroxydaunomycin
14-Hydroxydaunorubicine
14-hydroxydaunomycin
14-hydroxydaunorubicine
23214-92-8
23257-17-2
24385-08-8
25311-50-6
25316-40-9
25316-40-9 (hydrochloride)
29042-30-6
AC1L1M5T
AC1Q29OJ
ADM
ADR
Adriablastin
Adriacin (hydrochloride salt)
Adriamycin
Adriamycin PFS
Adriamycin PFS (hydrochloride salt)
Adriamycin RDF
Adriamycin RDF (hydrochloride salt)
Adriamycin Semiquinone
Adriamycin semiquinone
Adriblas tina
Adriblastin
Adriblastina
Adriblastina (TN)
Adriblastina (hydrochloride salt)
Aerosolized Doxorubicin
BPBio1_000502
BRD-K92093830-003-04-3
BSPBio_000456
BSPBio_001031
C01661
C27H29NO11
CCRIS 739
CHEBI:28748
CHEMBL179
CID31703
Caelyx
Conjugate of doxorubicin with humanized monoclonal antibody LL1 against CD74
Conjugate of doxorubicin with monoclonal antibody P4/D10 against GP120
D03899
DB00997
DM2
DOX-SL
Doxil
Doxo
Doxorubicin
Doxorubicin (USAN/INN)
Doxorubicin HCl
 
Doxorubicin Hydrochloride
Doxorubicin [USAN:INN:BAN]
Doxorubicin citrate
Doxorubicin hydrochloride (hydrochloride salt)
Doxorubicin-P4/D10
Doxorubicin-P4/D10 conjugate
Doxorubicin-hLL1
Doxorubicin-hLL1 conjugate
Doxorubicina
Doxorubicina [INN-Spanish]
Doxorubicine
Doxorubicine [INN-French]
Doxorubicinum
Doxorubicinum [INN-Latin]
EINECS 245-495-6
FI 106
Farmablastina (hydrochloride salt)
HMS2089H06
HSDB 3070
Hydroxydaunomycin hydrochlor ide (hydrochloride salt)
Hydroxydaunomycin hydrochloride (hydrochloride salt)
Hydroxydaunorubicin
Hydroxydaunorubicin hydrochloride (hydrochloride salt)
JT9100000
LMPK13050001
LS-1029
LS-165655
MLS000759533
Myocet
NCI-C01514
NChemBio.2007.10-comp13
NDC 38242-874
NIOSH/JT9100000
NSC 123127
Prestwick0_000438
Prestwick1_000438
Prestwick2_000438
Prestwick3_000438
Probes1_000151
Probes2_000129
RDF Rubex
Resmycin
Rubex
Rubex (hydrochloride salt)
SMP1_000106
SPBio_002395
TLC D-99
ThermoDox
Triferric doxorubicin
UNII-80168379AG
adiblastine (hydrochloride salt)
adr iablatina (hydrochloride salt)
adriablastine (hydrochloride salt)
adriablatina (hydrochloride salt)
adriblatina (hydrochloride salt)
doxorubicin
nchembio809-comp5
7
Vincristineapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 19222068-78-2, 57-22-75978
Synonyms:
22-Oxovincaleukoblastin
22-Oxovincaleukoblastine
28379-27-3
57-22-7
AC1L1LJC
C07204
C46H56N4O10
CCRIS 5763
CHEBI:28445
CID5978
D08679
DB00541
EINECS 200-318-1
HMS2090E19
HSDB 3199
Indole alkaloid
LCR
LS-228
Leurocristine
Lilly 37231 (1:1 sulfate salt)
Liposomal Vincristine
Marqibo
NCGC00163700-01
NCI-C04864
NCI60_026703
NSC-67574
Onco TCS
 
Oncovin
Oncovin (1:1 sulfate salt)
Oncovine
Tecnocris
Tecnocris (TN)
UNII-5J49Q6B70F
VCR
VIN
Vincaleukoblastine, 22-oxo- 22-Oxovincaleukoblastine
Vincasar
Vincasar (1:1 sulfate salt)
Vincasar PFS
Vincrex
Vincrex (1:1 sulfate salt)
Vincristin
Vincristina
Vincristina [DCIT]
Vincristine (INN)
Vincristine Sulfate
Vincristine Sulfate PFS
Vincristine [INN:BAN]
Vincristinum
Vincristinum [INN-Latin]
Vincrstine
Vincrystine
Vinkristin
Z-D-Val-Lys(Z)-OH
vincristine
8
Dexamethasoneapproved, investigational, vet_approvedPhase 4, Phase 3, Phase 1, Phase 2217150-02-25743
Synonyms:
(3H)-Dexamethasone
.delta.(sup 1)-9-.alpha.-Fluoro-16-.alpha.-methylcortisol
.gamma.corten
1-Dehydro-16.alpha.-methyl-9.alpha.-fluorohydrocortisone
1-Dehydro-16alpha -methyl-9alpha -fluorohydrocortisone
1-Dehydro-16alpha-methyl-9alpha-fluorohydrocortisone
1-Dehydro-16α-methyl-9α-fluorohydrocortisone
137098-19-2
16-alpha-Methyl-9-alpha-fluoro-1-dehydrocortisol
16-alpha-Methyl-9-alpha-fluoro-delta(sup 1)-hydrocortisone
16-alpha-Methyl-9-alpha-fluoro-delta1-hydrocortisone
16-alpha-Methyl-9-alpha-fluoroprednisolone
16.alpha.-Methyl-9.alpha.-fluoro-1-dehydrocortisol
16.alpha.-Methyl-9.alpha.-fluoroprednisolone
16alpha -Methyl-9alpha -fluoro-1-dehydrocortisol
16alpha -Methyl-9alpha -fluoroprednisolone
16alpha-Methyl-9alpha-fluoro-1-dehydrocortisol
16alpha-Methyl-9alpha-fluoro-delta(sup 1)-hydrocortisone
16alpha-Methyl-9alpha-fluoroprednisolone
16α-Methyl-9α-fluoro-1-dehydrocortisol
23495-06-9
31375_FLUKA
46165_FLUKA
46165_RIEDEL
50-02-2
8054-59-9
9-Fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione
9-Fluoro-11alpha -methylpregna-1,4-diene-3,20-dione
9-Fluoro-16-methylprednisolone
9-alpha-Fluoro-16-alpha-methylprednisolone
9.alpha.-Fluoro-16.alpha.-methylprednisolone
906422-84-2
9A-FLUORO-16BETA-METHYLPREDNISOLONE
9alpha -Fluoro-16alpha -methylprednisolone
9alpha-Fluoro-16alpha-methylprednisolone
9alpha-fluoro-16alpha-methyl-Prednisolone
9α-Fluoro-16α-methylprednisolone
AC-11056
AC1L1L1H
AC1Q29DM
AI3-50934
Adexone
Aeroseb-D
Aeroseb-Dex
Aeroseb-dex
Ak Dex Oph Otic Soln 0.1%
Alcon Brand of Dexamethasone
Anaflogistico
Aphtasolon
Aphthasolone
Apo-dexamethasone
Auxiron
Azimycin (veterinary)
Azium
Azium (Veterinary)
Azium (veterinary)
BIDD:ER0494
BIDD:PXR0060
BRD-K38775274-001-02-3
BRD-K38775274-001-06-4
BSPBio_000995
Bisu DS
Bisu Ds
C15643
C22H29FO5
CCRIS 7067
CHEBI:41879
CHEMBL384467
CID5743
CPD-10549
CPD001227192
Calonat
Corson
Corsone
Cortisumman
D00292
D003907
D1756_SIGMA
D4902_SIGMA
D6645_SIGMA
D8893_SIGMA
D9184_SIGMA
DB01234
DEX
DEXA
DEXONE 0.5
DEXONE 0.75
DEXONE 1.5
DEXONE 4
DXM
DXMS
Decacort
Decacortin
Decaderm
Decadron
Decadron (TN)
Decadron Tablets, Elixir
Decadron, Dexamethasone
Decadron-LA
Decadron-La
Decagel
Decaject
Decaject L.A.
Decaject-L.A.
Decalix
Decameth
Decasone
Decaspray
Dectancyl
Dekacort
Delta1-9alpha-Fluoro-16alpha-methylcortisol
Deltafluorene
Dergramin
Deronil
Desadrene
Desametasone
Desametasone [DCIT]
Desametasone [Dcit]
Desamethasone
Desameton
Deseronil
Dex-Ide
Dex-ide
Dexa
Dexa Mamallet
Dexa mamallet
Dexa-Cortidelt
Dexa-Cortisyl
Dexa-Mamallet
Dexa-Scheroson
Dexa-Sine
Dexa-cortidelt
Dexa-cortisyl
Dexa-scheroson
Dexa-sine
Dexacen-4
Dexacidin
Dexacort
Dexacortal
Dexacortin
Dexadeltone
Dexafarma
Dexair
Dexalona
Dexaltin
Dexametasona
Dexametasona [INN-Spanish]
Dexametasone
 
Dexameth
Dexamethansone
Dexamethasone
Dexamethasone (JP15/USP/INN)
Dexamethasone Acetate
Dexamethasone Alcohol
Dexamethasone Base
Dexamethasone Intensol
Dexamethasone Sodium Phosphate
Dexamethasone [INN:BAN:JAN]
Dexamethasone alcohol
Dexamethasone base
Dexamethasone intensol
Dexamethasone-omega
Dexamethasonum
Dexamethasonum [INN-Latin]
Dexamethazone
Dexamonozon
Dexapolcort
Dexapos
Dexaprol
Dexason
Dexasone
Dexasone 0.5mg
Dexasone 0.75mg
Dexasone 4mg
Dexasporin
Dexinolon
Dexinoral
Dexone
Dexone 0.5
Dexone 0.75
Dexone 1.5
Dexone 4
Dexonium
Dexpak
Dextelan
Dezone
Dinormon
Dxms
ECR Brand of Dexamethasone
EINECS 200-003-9
FT-0080377
Fluormethylprednisolone
Fluormone
Fluorocort
Fortecortin
Foy Brand of Dexamethasone
Gammacorten
HL-dex
HMS1792A17
HMS1990A17
HMS2089N13
HSDB 3053
Hexadecadrol
Hexadrol
Hexadrol Elixir
Hexadrol Tablets
Hexadrol elixir
Hl-Dex
Hl-dex
I06-1196
ICN Brand of Dexamethasone
IontoDex
Isopto-Dex
Isopto-dex
LS-7300
Lokalison F
Lokalison f
Loverine
Luxazone
MK 125
MLS001055412
MLS001332507
MLS001332508
Maxidex
Maxidex Ont 0.1%
Maxidex Sus 0.1%
Maxitrol
Mediamethasone
Merck Brand of Dexamethasone
Merz Brand 1 of Dexamethasone
Merz Brand 2 of Dexamethasone
Methylfluorprednisolone
Mexidex
Millicorten
MolMap_000018
MolPort-003-846-433
Mymethasone
NCGC00091019-01
NCGC00091019-02
NCGC00091019-03
NCGC00091019-04
NCGC00091019-05
NCI60_003067
NSC 34521
NSC34521
Naquasone (veterinary)
Neomycin and polymyxin b sulfates and dexamethasone
Neomycin and polymyxin b sulphates and dexamethasone
OTO-104
Ocu-Trol
Ocu-trol
Oradexon
PHL-dexamethasone
PMS-dexamethasone
Pet Derm III
Pet Derm Iii
Pet derm III
Pet-Derm Iii
Pms Dexamethasone Elixir 0.5mg/5ml
Policort
Posurdex
Prednisolon F
Prednisolon f
Prednisolone F
Prednisolone f
Prodex
S1322_Selleck
SAM002548948
SGCUT00126
SK-Dexamethasone
SK-dexamethasone
SMP1_000092
SMR000857119
SMR001227192
ST50307091
Sandoz dexamethasone
Sk-Dexamethasone
Spectrum5_002019
Spoloven
Sunia Sol D
Sunia sol D
Superprednol
TL8003317
Tobradex
Tobramycin and dexamethasone
Tresaderm (veterinary)
Turbinaire
UNII-7S5I7G3JQL
Visumetazone
WLN: L E5 B666 OV KU MUTJ A1 BF CQ E1 FV1Q FQ G1
ZINC03875332
alpha -Fluoro-16-alpha -methylcortisol
delta(Sup 1)-9-alpha-Fluoro-16-alpha-methylcortisol
delta(sup 1)-9-alpha-Fluoro-16-alpha-methylcortisol
delta1-9alpha-Fluoro-16alpha-methylcortisol
dexamethasone
nchembio809-comp2
to_000038
9
Miconazoleapproved, investigational, vet_approvedPhase 4, Phase 3, Phase 2, Phase 1370622916-47-84189
Synonyms:
(+-)-1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl) imidazole
1-[2,4-Dichloro- beta-([2,4-dichloro- benzyl]oxy)phenethyl]imidazole
1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole
1-[2-(2,4-Dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole
1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole
1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole
1-[2-(2,4-dichlorophenyl)-2-{[(2,4-dichlorophenyl)methyl]oxy}ethyl]-1H-imidazole
1-{2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole
22832-87-7 (NITRATE)
22916-47-8
75319-47-0
AB00053500
AC1L1HM1
AKOS001574474
Aflorix(nitrate)
Albistat(nitrate)
Andergin(nitrate)
BPBio1_000279
BRD-A82396632-001-03-0
BRD-A82396632-008-02-7
BRN 0965511
BSPBio_000253
BSPBio_002033
CCRIS 7924
CHEBI:6923
CHEMBL91
CID4189
CPD-4501
Conofite(nitrate)
D00416
DB01110
Dactarin
Daktarin IV
Daktarin iv
DivK1c_000156
EINECS 245-324-5
Epi-Monistat(nitrate)
Femizol-M
Florid(nitrate)
Gyno-Daktar(nitrate)
HMS1568M15
HMS2090B21
I14-14342
IDI1_000156
Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)- (9CI)
KBio1_000156
KBio2_001445
KBio2_004013
KBio2_006581
KBio3_001533
KBioGR_000581
KBioSS_001445
LS-78378
Lotrimin AF(nitrate)
MCZ
MJR 1762
MLS002222203
Micantin (nitrate)
Miconasil Nitrate
 
Miconazol
Miconazol [INN-Spanish]
Miconazole
Miconazole (JP15/USP/INN)
Miconazole 3
Miconazole 3 Combination Pack
Miconazole 7 Combination Pack
Miconazole [USAN:BAN:INN:JAN]
Miconazole nitrate salt
Miconazole-7
Miconazolo
Miconazolo [DCIT]
Miconazolum
Miconazolum [INN-Latin]
Micozole
Minostate
MolPort-002-557-553
Monazole 7
Monista (nitrate)
Monistat
Monistat (TN)
Monistat 1 Combination Pack
Monistat 3 Dual-Pak
Monistat 3 Vaginal Ovules
Monistat 5 Tampon
Monistat 7 Dual-Pak
Monistat 7 Vaginal Suppositories
Monistat Dual- PAK
Monistat IV
Monistat iv (TN)
Monistat iv (tn)
Monistat-Derm
NCI60_001353
NCI60_001380
NINDS_000156
NSC 170986
NSC169434
NSC170986
Novo-Miconazole Vaginal Ovules
Oprea1_091955
Prestwick0_000067
Prestwick1_000067
Prestwick2_000067
Prestwick3_000067
Prestwick_335
R 18134
R-14,889
SMR001307249
SPBio_000976
SPBio_002174
STK834405
STOCK1S-93556
Spectrum2_001048
Spectrum3_000507
Spectrum4_000061
Spectrum5_001297
Spectrum_000965
UNII-7NNO0D7S5M
Vusion
Zimycan
imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl) methoxy)ethyl)- (9CI)
miconazole
10
Sirolimusapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 1194053123-88-95284616, 6436030, 46835353
Synonyms:
(-)-Rapamycin
(-)-rapamycin
1fkb
1pbk
23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine
23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine
23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29
3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
53123-88-9
A422989, NSC226080
AC-722
AC1L1JH9
AC1L7MJ9
AC1L9ZMV
AY 22989
AY-22989
AY22989
Ambotz53123-88-9
Antibiotic AY 22989
BIDD:PXR0165
Bio1_000293
Bio1_000782
Bio1_001271
Bio2_000375
Bio2_000855
BiomolKI2_000084
C07909
C51H79NO13
CBiol_002007
CCRIS 9024
CHEBI:100923
CHEBI:9168
CHEMBL413
CID10213190
CID10795871
CID11949238
CID11959112
CID313006
CID478951
CID5040
CID5284616
CID5358081
CID5374464
CID5460439
CID5497196
CID5924240
CID6436030
CID6610270
CID6610346
CID6711160
CID6713081
CID9833581
CID9854379
CID9854380
CID9962926
CID9962928
D00753
DB00877
DE-109
DivK1c_006936
 
FT-0082351
HMS2089A21
HSDB 7284
KBio1_001880
KBio2_000410
KBio2_002978
KBio2_005546
KBio3_000779
KBio3_000780
KBioGR_000410
KBioSS_000410
LCP-Siro
LMPK06000003
LS-143290
MLS000028373
MS-R001
MolMap_000043
MolPort-003-959-433
NCGC00021305-05
NCI60_001851
NCIMech_000355
NSC 226080
NSC226080
Perceiva
QTL1_000069
R0395_SIAL
R0395_SIGMA
RAP
RAPA
RPM
Rapammune
Rapamune
Rapamune (TN)
Rapamycin
Rapamycin (TN)
Rapamycin C-7, analog 4
Rapamycin Immunosuppressant Drug
Rapamycin from Streptomyces hygroscopicus
S1039_Selleck
SIIA 9268A
SILA 9268A
SILA9268A
SMP1_000255
SMR000058564
Sirolimus
Sirolimus (RAPAMUNE)
Sirolimus (USAN/INN)
Sirolimus [USAN:BAN:INN]
Sirolimus, Rapamune,Rapamycin
SpecPlus_000840
UNII-W36ZG6FT64
UNM-0000358684
WY-090217
Wy 090217
heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy
nchembio.100-comp4
nchembio.2007.42-comp2
nchembio.79-comp1
nchembio762-comp1
nchembio883-comp3
rapamycin
sirolimus
11
EverolimusapprovedPhase 4, Phase 3, Phase 2, Phase 11940159351-69-66442177
Synonyms:
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,23S,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriacont
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-3-{(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl}-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34as)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethy
07741_FLUKA
159351-69-6
40-O-(2-hydroxyethyl)-rapamycin
42-O-(2-Hydroxyethyl)rapamycin
Afinitor
CERTICAN(R)
CHEMBL1201755
Certican
D02714
DB01590
 
Everolimus
Everolimus (JAN/USAN/INN)
Everolimus [USAN]
LS-143292
MolPort-003-847-342
MolPort-003-925-588
NCGC00167512-01
NVP-RAD-001
RAD 001
RAD-001
RAD-001C
RAD001
RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus
S1120_Selleck
SDZ-RAD
UNII-9HW64Q8G6G
Zortress
everolimus
12
Cyclophosphamideapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 1293550-18-0, 6055-19-22907
Synonyms:
(+-)-Cyclophosphamide
(-)-Cyclophosphamide
(RS)-Cyclophosphamide
1-(bis(2-chloroethyl)amino)-1-oxo-2-aza-5-oxaphosphoridine
1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin
2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide
4-Hydroxy-cyclophosphan-mamophosphatide
50-18-0
60007-95-6
6055-19-2 (monohydrate)
75526-90-8
AC1L1EQQ
AI3-26198
ASTA
ASTA B518
Anhydrous cyclophosphamide
Asta B 518
B 518
B-518
BRN 0011744
BSPBio_002099
Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
C 0768
C07888
C7H15Cl2N2O2P
CB 4564
CB-4564
CCRIS 188
CHEBI:4027
CHEMBL32520
CHEMBL88
CID2907
CP
CPA
CTX
CY
Ciclofosfamida
Ciclofosfamida [INN-Spanish]
Ciclofosfamide
Ciclophosphamide
Ciclophosphamide [INN]
Clafen
Claphene
Cycloblastin
Cyclophosphamid
Cyclophosphamide
Cyclophosphamide (INN)
Cyclophosphamide (TN)
Cyclophosphamide (anhydrous form)
Cyclophosphamide (anhydrous)
Cyclophosphamide Monohydrate
Cyclophosphamide Sterile
Cyclophosphamide anhydrous
Cyclophosphamide, (+-)-Isomer
Cyclophosphamides
Cyclophosphamidum
Cyclophosphamidum [INN-Latin]
Cyclophosphan
Cyclophosphane
Cyclophosphanum
Cyclophosphoramide
Cyclostin
Cyklofosfamid
Cyklofosfamid [Czech]
Cytophosphan
Cytophosphane
Cytoxan
Cytoxan (TN)
Cytoxan Lyoph
D,L-Cyclophosphamide
D07760
 
DB00531
DivK1c_000246
EINECS 200-015-4
EU-0100238
Endoxan
Endoxan R
Endoxan-Asta
Endoxana
Endoxanal
Endoxane
Enduxan
Genoxal
HMS2090A12
HSDB 3047
Hexadrin
IDI1_000246
KBio1_000246
KBio2_001338
KBio2_003906
KBio2_006474
KBio3_001319
KBioGR_000888
KBioSS_001338
LS-1302
LS-99787
Ledoxina
Lopac-C-0768
Lopac0_000238
Lyophilized Cytoxan
Mitoxan
MolPort-001-783-420
N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
NCGC00015209-01
NCGC00015209-03
NCGC00015209-06
NCGC00091741-02
NCGC00091741-03
NCI-C04900
NCI60_002097
NINDS_000246
NSC 26271
NSC-26271
NSC26271
NSC273033
NSC273034
Neosar
Occupation, cyclophosphamide exposure
Procytox
RCRA waste no. U058
Rcra Waste Number U058
Rcra waste number U058
Revimmune
S1217_Selleck
SK 20501
SPBio_001071
STK177249
STOCK2S-91217
Semdoxan
Sendoxan
Senduxan
Spectrum2_001146
Spectrum3_000370
Spectrum4_000304
Spectrum5_000795
Spectrum_000858
UNII-6UXW23996M
WLN: T6MPOTJ BO BN2G2G
Zyklophosphamid
Zyklophosphamid [German]
bis(2-Chloroethyl)phosphami de cyclic propanolamide
bis(2-Chloroethyl)phosphamide cyclic propanolamide ester
cyclophosphamide
13
LenograstimapprovedPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 11220135968-09-1
Synonyms:
G-CSF (CHO cell derived)
Glycosylated recombinant G-CSF
Glycosylated recombinant granulocyte colony stimulating factor
 
Granulocyte colony stimulating factor 3 (CHO cell derived)
Granulocyte colony-stimulating factor lenograstim
Lenograstim (genetical recombination)
Lenograstim rDNA
14
ThiotepaapprovedPhase 4, Phase 2, Phase 3, Phase 122652-24-45453
Synonyms:
 
Thioplex
15
DoxilApproved June 1999Phase 4, Phase 3, Phase 2, Phase 1175131703
Synonyms:
Dox-SL
Doxil
 
Evacet
LipoDox
Pegylated Liposomal Doxorubicin Hydrochloride
liposomal doxorubicin
16Gastrointestinal AgentsPhase 4, Phase 3, Phase 1, Phase 28402
17Etoposide phosphatePhase 4, Phase 3, Phase 2, Phase 1, Early Phase 11269
18glucocorticoidsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 15103
19Peripheral Nervous System AgentsPhase 4, Phase 3, Phase 1, Phase 223689
20Topoisomerase InhibitorsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 15069
21Antifungal AgentsPhase 4, Phase 3, Phase 2, Phase 13696
22Alkylating AgentsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 14827
23Dexamethasone acetatePhase 4, Phase 3, Phase 1, Phase 221711177-87-3
24Hormones, Hormone Substitutes, and Hormone AntagonistsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 113168
25Hormone AntagonistsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 113180
26HormonesPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 114415
27HIV Protease InhibitorsPhase 4, Phase 3, Phase 1, Phase 25470
28
protease inhibitorsPhase 4, Phase 3, Phase 1, Phase 25471
Synonyms:
 
protease inhibitors
29Angiogenesis Modulating AgentsPhase 4, Phase 3, Phase 2, Phase 14185
30Anti-Bacterial AgentsPhase 4, Phase 3, Phase 2, Phase 111226
31Antibiotics, AntitubercularPhase 4, Phase 3, Phase 2, Phase 17180
32AntiemeticsPhase 4, Phase 3, Phase 1, Phase 24022
33Immunosuppressive AgentsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 113086
34Antirheumatic AgentsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 110956
35Dexamethasone 21-phosphatePhase 4, Phase 3, Phase 1, Phase 22171
36Antilymphocyte SerumPhase 4, Phase 2, Phase 3, Phase 1408
37Antineoplastic Agents, AlkylatingPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 14603
38Anti-Infective AgentsPhase 4, Phase 3, Phase 2, Phase 122062
39Angiogenesis InhibitorsPhase 4, Phase 3, Phase 2, Phase 14257
40BB 1101Phase 4, Phase 3, Phase 1, Phase 22171
41Antiviral AgentsPhase 4, Phase 3, Phase 1, Phase 29967
42Anti-Inflammatory AgentsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 110729
43Autonomic AgentsPhase 4, Phase 3, Phase 1, Phase 210150
44Antineoplastic Agents, HormonalPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 15592
45Antineoplastic Agents, PhytogenicPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 15602
46Antimetabolites, AntineoplasticPhase 4, Phase 3, Phase 2, Phase 17361
47AntimetabolitesPhase 4, Phase 3, Phase 2, Phase 112054
48Antimitotic AgentsPhase 4, Phase 3, Phase 2, Phase 15657
49
OfloxacinapprovedPhase 323682419-36-14583
Synonyms:
( -)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)(1,4)benzoxazin-6-carbonsaeure
(+-)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid
(+/-)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperaz inyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid
(+/-)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7- -oxo-7H-pyrido(1,2,3-de)- -1,4-benzoxazine-6-carboxylic acid
(+/-)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid
(+/-)-Floxin
118120-51-7 (hydrochloride)
33703_FLUKA
33703_RIEDEL
8-Fluoro-3-methyl-9-(4-methyl-piperazin-1-yl)-6-oxo-2,3-dihydro-6H-1-oxa-3a-aza-phenalene-5-carboxylic acid
82419-36-1
83380-47-6
85344-55-4
9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid
AB00513820
AC-7616
AC1L1IHM
AKOS001033517
BB_SC-1252
BPBio1_000345
BRD-A24228527-001-05-9
BRN 3657947
BSPBio_000313
BSPBio_003117
Bactocin
C07321
C18H20FN3O4
CCRIS 5233
CHEBI:7731
CHEMBL4
CID4583
CPD000058192
D00453
DB01165
DEXTROFLOXACINE
DL 8280
DL-8280
DL-8280, HOE-280, Exocin, Flobacin, Floxin, Floxil, Monoflocet, Ofloxacin
Danoflox
DivK1c_000721
EU-0100904
Effexin
Exocin
Exocine
FLOXIN IN DEXTROSE 5%
FLOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER
Flobacin
Flodemex
Flotavid
Flovid
Floxal
Floxil
Floxin
Floxin (TN)
Floxin otic
Floxstat
Fugacin
HMS1568P15
HMS1921H12
HMS2090F07
HMS2092B10
HMS502E03
HOE 280
Hoe-280
I06-0112
I06-0380
IDI1_000721
Inoflox
KBio1_000721
KBio2_001666
KBio2_004234
KBio2_006802
KBio3_002617
KBioGR_000667
KBioSS_001666
Kinflocin
Kinoxacin
LS-133259
Liflox
Lopac0_000904
Loxinter
MLS000028749
MLS001074203
Marfloxacin
Medofloxine
Mergexin
MolPort-000-422-241
MolPort-000-873-068
NCGC00015772-02
NCGC00015772-10
 
NCGC00094219-01
NCGC00094219-02
NCGC00094219-03
NCGC00094219-04
NCGC00094219-05
NCGC00094219-06
NCGC00178284-01
NCGC00178284-02
NINDS_000721
NSC727071
Novecin
Nufafloqo
O 8757
O-Flox
O8757_SIGMA
OFLX
OFX
ORF 18489
ORF-28489
Obide
Occidal
Ocuflox
Ofcin
Oflin
Oflocee
Oflocet
Oflocin
Oflodal
Oflodex
Oflodura
Oflox
Ofloxacin (JP15/USP/INN)
Ofloxacin Otic
Ofloxacin [USAN:BAN:INN:JAN]
Ofloxacin, (S)-Isomer
Ofloxacina
Ofloxacina [DCIT]
Ofloxacine
Ofloxacine [French]
Ofloxacino
Ofloxacino [Spanish]
Ofloxacinum
Ofloxacinum [Latin]
Ofloxin
Ofus
Onexacin
Operan
Oprea1_242882
Orocin
Otonil
Oxaldin
PT 01
Pharflox
Praxin
Prestwick0_000237
Prestwick1_000237
Prestwick2_000237
Prestwick3_000237
Puiritol
Qinolon
Qipro
Quinolon
Quotavil
Rilox
Ru-43280
S1463_Selleck
SAM002264629
SMR000058192
SPBio_001387
SPBio_002234
SPECTRUM1502044
STK256723
Sinflo
Spectrum2_001464
Spectrum3_001499
Spectrum4_000324
Spectrum5_001063
Spectrum_001186
Tabrin
Taravid
Tariflox
Tarivid
Telbit
Tructum
UNII-A4P49JAZ9H
Uro Tarivid
Viotisone
Visiren
WP-0405
XED
Zanocin
ofloxacin
50
CarboplatinapprovedPhase 2, Phase 3, Phase 1, Early Phase 1205041575-94-410339178, 498142, 38904
Synonyms:
(SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum
/h1-3H2,(H,7,8)(H,9,10)
/q
1,1-Cyclobutanedicarboxylate diammine platinum (II)
1,1-Cyclobutanedicarboxylate diammine platinum(II)
2*-1
2*1H2
41575-94-4
70903-55-8
AC-1457
AC1L8I6U
Ambap41575-94-4
BSPBio_003145
C 2538
C2043
C2538_SIGMA
C6H10N2O4Pt
CBDCA
CCRIS 3404
CHEBI:31355
CHEMBL1351
CHEMBL288376
CID10339178
CID2567
CID38904
CID426756
CID498142
CID5352133
CID6398587
CID6603770
Carbopaltin
Carboplatin
Carboplatin (JAN/USP/INN)
Carboplatin (USAN)
Carboplatin [USAN:INN:BAN:JAN]
Carboplatine
Carboplatine [French]
Carboplatino
Carboplatino [Spanish]
Carboplatinum
Carboplatinum [Latin]
Cbdca
Cyclobutane-1,1-dicarboxylate
D01363
DB00958
Diammine(1,1-cyclobutanedicarboxylato)platinum (II)
Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum
Diammine-1,1-cyclobutane dicarboxylate platinum II
DivK1c_000892
EINECS 255-446-0
EU-0100230
Ercar
HMS1921J16
HMS2090M05
HMS2092B22
HMS502M14
HSDB 6957
I14-2390
IDI1_000892
IUPAC: Azane
InChI=1/C6H8O4.2H2N.Pt/c7-4(8)6(5(9)10)2-1-3-6
 
JM 8
JM-8
KBio1_000892
KBio2_002009
KBio2_004577
KBio2_007145
KBio3_002645
KBioGR_000713
KBioSS_002009
LS-117689
Lopac-C-2538
Lopac0_000230
MolPort-003-665-501
MolPort-003-845-609
NCGC00015223-01
NCGC00093695-01
NCGC00094961-01
NCGC00094961-02
NCGC00094961-03
NCGC00162099-01
NCGC00162099-02
NCGC00167800-01
NCGC00178242-01
NINDS_000892
NSC 201345
NSC 241240
NSC-241240
NSC201345
NSC241240
Paraplatin
Paraplatin (TN)
Paraplatin, Carboplatin
Paraplatin-AQ
Platinum(+2) Cation
Platinum(II), (1, 1-cyclobutanedicar
Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2)
Platinum, {diammine[1,1-cyclobut
S1215_Selleck
SPBio_000716
SPECTRUM1502106
Spectrum2_000898
Spectrum3_001503
Spectrum4_000337
Spectrum5_001094
Spectrum_001529
UNII-BG3F62OND5
azanide
carboplatin
cis -Diammine[1,1-cyclobutane-dicarboxylato] platinum
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II)
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(ii)
cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II)
cis-Diammine(1,1-cyclobutanedicarboxylato) platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diammine(cyclobutanedicarboxylato)platinum II
cyclobutane-1,1-dicarboxylic acid
diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum
nchembio.573-comp10
nchembio773-comp2
nchembio873-comp3
platinum(2+)

Interventional clinical trials:

(show top 50)    (show all 942)
idNameStatusNCT IDPhase
1Bone Marrow Transplantation in Treating Patients With Hematologic CancerCompletedNCT00003398Phase 4
2EDOCH Alternating With DHAP for New Diagnosed Younger MCLRecruitingNCT02858804Phase 4
3An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell LymphomaActive, not recruitingNCT01833039Phase 4
4Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell LymphomaActive, not recruitingNCT01180049Phase 4
5Chemotherapy Followed by Radiation Therapy and Peripheral Stem Cell Transplant Compared With Chemotherapy Plus Interferon Alfa in Treating Patients With Stage III or Stage IV Mantle Cell LymphomaUnknown statusNCT00016887Phase 3
6Fludarabine and Cyclophosphamide With or Without Rituximab in Treating Patients With Previously Untreated Mantle Cell LymphomaUnknown statusNCT00641095Phase 3
7Efficacy of R-CHOP vs R-CHOP/R-DHAP in Untreated MCLUnknown statusNCT00209222Phase 3
8Radiolabeled Monoclonal Antibody in the Detection and Staging of Patients With Non-Hodgkin's LymphomaUnknown statusNCT00003337Phase 3
9Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's LymphomaUnknown statusNCT00003338Phase 2, Phase 3
10Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Non-Hodgkin's LymphomaUnknown statusNCT00052936Phase 3
11Combination Chemotherapy Followed By Radiation Therapy in Treating Patients With Aggressive Non-Hodgkin's LymphomaUnknown statusNCT00053768Phase 3
12Combination Chemotherapy Plus Filgrastim With or Without Rituximab in Treating Older Patients With Non-Hodgkin's LymphomaUnknown statusNCT00028717Phase 3
13Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic SyndromeUnknown statusNCT00002989Phase 3
14Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and NeutropeniaUnknown statusNCT00020865Phase 3
15Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile NeutropeniaUnknown statusNCT00445497Phase 3
16Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic PainUnknown statusNCT01316744Phase 3
17Interferon Alfa-2b Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Hodgkin's Disease or Non-Hodgkin's LymphomaUnknown statusNCT00003924Phase 3
18Combination Chemotherapy Given With Radiation Therapy or Radiation Therapy Alone in Treating Patients With Early-Stage Hodgkin's DiseaseUnknown statusNCT00002987Phase 3
19Study of Ibrutinib (a Bruton's Tyrosine Kinase Inhibitor), Versus Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior TherapyCompletedNCT01646021Phase 3
20Monoclonal Antibody Therapy in Treating Patients With Follicular or Mantle Cell LymphomaCompletedNCT00003280Phase 3
21Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)CompletedNCT00117598Phase 3
22Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL)CompletedNCT01073163Phase 3
23Bendamustine Plus Rituximab Versus Fludarabine Plus RituximabCompletedNCT01456351Phase 3
24Mantel Cell Lymphoma Efficacy of Rituximab MaintenanceCompletedNCT00921414Phase 3
25Bendamustine Plus Rituximab Versus CHOP Plus RituximabCompletedNCT00991211Phase 3
26A Study of MabThera (Rituximab) in Patients With Advanced Non-Hodgkin's LymphomaCompletedNCT00269113Phase 3
27Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late ComplicationsCompletedNCT00799461Phase 3
28Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic CancerCompletedNCT00075478Phase 3
29Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or LymphomaCompletedNCT00005590Phase 3
30Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By ChemotherapyCompletedNCT00003341Phase 3
31Rituximab and Combination Chemotherapy in Treating Patients With Non-Hodgkin's LymphomaCompletedNCT00278421Phase 3
32Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's LymphomaCompletedNCT00278408Phase 3
33Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell CountCompletedNCT00003805Phase 3
34St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for CancerCompletedNCT00005805Phase 3
35Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a CatheterCompletedNCT00006083Phase 3
36Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With CancerCompletedNCT00661999Phase 3
37Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for CancerCompletedNCT00070382Phase 3
38Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical TrialCompletedNCT00750009Phase 3
39American Ginseng in Treating Patients With Fatigue Caused by CancerCompletedNCT00719563Phase 3
40Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer PainCompletedNCT00666211Phase 3
41Combination Chemotherapy With or Without Rituximab in Treating Patients With Newly Diagnosed Non-Hodgkin's LymphomaCompletedNCT00004112Phase 3
42Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer TreatmentCompletedNCT00008359Phase 3
43Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer PatientsCompletedNCT00003938Phase 3
44Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer PainCompletedNCT00538850Phase 3
45Laboratory-Treated Donor Bone Marrow in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic CancerCompletedNCT00265837Phase 3
46Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell TransplantationCompletedNCT00014391Phase 3
47Itraconazole Compared With Fluconazole to Prevent Infections in Patients Undergoing Peripheral Stem Cell or Bone Marrow TransplantationCompletedNCT00003883Phase 3
48Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell TransplantCompletedNCT00305851Phase 3
49Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell TransplantationCompletedNCT00004230Phase 3
50Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell TransplantationCompletedNCT00045292Phase 3

Search NIH Clinical Center for Mantle Cell Lymphoma

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Mantle Cell Lymphoma cell therapies at LifeMap Discovery.

Genetic Tests for Mantle Cell Lymphoma

About this section

Genetic tests related to Mantle Cell Lymphoma:

id Genetic test Affiliating Genes
1 Mantle Cell Lymphoma27

Anatomical Context for Mantle Cell Lymphoma

About this section

MalaCards organs/tissues related to Mantle Cell Lymphoma:

36
B cells, Bone, Bone marrow, T cells, Lymph node, Monocytes, Colon

Publications for Mantle Cell Lymphoma

About this section

Articles related to Mantle Cell Lymphoma:

(show top 50)    (show all 1019)
idTitleAuthorsYear
1
Recommendations for Clinical Trial Development in Mantle Cell Lymphoma. (28040733)
2017
2
Gastrointestinal mantle cell lymphoma with isolated mass and multiple lymphomatous polyposis: report of two cases. (28451951)
2017
3
SOX11 promotes tumor protective microenvironment interactions through CXCR4 and FAK regulation in mantle cell lymphoma. (28533307)
2017
4
Novel agents in mantle cell lymphoma. (28480764)
2017
5
Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma. (28416797)
2017
6
Cyclin D1-negative blastoid mantle cell lymphoma exhibiting cleaved to bilobated cytomorphology. (28495928)
2017
7
Mantle cell lymphoma with central nervous system involvement simulating bilateral subdural hematomas. (28063897)
2017
8
Second-line rituximab, lenalidomide, and bendamustine (R2B) in mantle cell lymphoma: a phase 2 clinical trial of the Fondazione Italiana Linfomi. (28082342)
2017
9
Mantle Cell Lymphoma: Contemporary Diagnostic and Treatment Perspectives in the Age of Personalized Medicine. (28404221)
2017
10
SOX-11 detection in decalcified bone marrow tissue in mantle cell lymphoma patients, methodological issue on reproducibility and validity. (28457728)
2017
11
SOX-11 detection in decalcified bone marrow tissue in mantle cell lymphoma patients, methodological issue on reproducibility and validity-reply. (28461033)
2017
12
Mantle Cell Lymphoma Presenting as a Subcutaneous Soft Tissue Mass With an Unusual Appearance. (28081018)
2017
13
Hyperfractionated Cyclophosphamide, Vincristine, Doxorubicin, and Dexamethasone Chemotherapy in Mantle Cell Lymphoma Patients Is Associated with Higher Rates of Hematopoietic Progenitor Cell Mobilization Failure despite Plerixafor Rescue. (28434928)
2017
14
Correction: ROS-Induced CXCR4 Signaling Regulates Mantle Cell Lymphoma (MCL) Cell Survival and Drug Resistance in the Bone Marrow Microenvironment via Autophagy. (28373366)
2017
15
The drive to generate multiple forms of oncogenic cyclin D1 transcripts in mantle cell lymphoma. (28503306)
2017
16
Results of a phase I-II study of fenretinide and rituximab for patients with indolent B-cell lymphoma and mantle cell lymphoma. (28055107)
2017
17
Targeting mantle cell lymphoma metabolism and survival through simultaneous blockade of mTOR and nuclear transporter exportin-1. (28388555)
2017
18
Triple-hit blastoid mantle cell lymphoma presenting like acute leukemia. (28473415)
2017
19
Numerous Ontogenetic Roads to Mantle Cell Lymphoma: Immunogenetic and Immunohistochemical Evidence. (28457696)
2017
20
SOX11 regulates the pro-apoptosis signal pathway and predicts a favorable prognosis of mantle cell lymphoma. (28429312)
2017
21
First reported case of disseminated Nocardia kroppenstedtii sp nov. infection presenting with brain abscess and endocarditis in an immunocompromised patient with mantle cell lymphoma: challenges in diagnosis and treatment. (28062425)
2017
22
Synergistic Cytotoxicity of Lenalidomide and Dexamethasone in Mantle Cell Lymphoma via Cereblon-dependent Targeting of the IL-6/STAT3/PI3K Axis. (28529032)
2017
23
Phase II Study of Bortezomib in Combination with Cyclophosphamide and Rituximab for Relapsed or Refractory Mantle Cell Lymphoma. (28408615)
2017
24
Expression of LEF1 in mantle cell lymphoma. (28038713)
2017
25
Persistence of a t(11;14)-positive clone in a patient with mantle cell lymphoma for 20A years. (28396772)
2017
26
Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory mantle cell lymphoma-a "real world" study. (28066928)
2017
27
Incidence and survival trends in mantle cell lymphoma. (28444739)
2017
28
Role of SOX11 and Genetic Events Cooperating with Cyclin D1 in Mantle Cell Lymphoma. (28466437)
2017
29
Androgen receptor expression in mantle cell lymphoma: Potential novel therapeutic implications. (28115200)
2017
30
Complementarity determining region-independent recognition of a superantigen by B-cell antigen receptors of mantle cell lymphoma. (27582571)
2016
31
Discrete vacuoles in lymphocytes as a subtle clue to mantle cell lymphoma. (28092871)
2016
32
Validation of R-MIPI and prognostic value of immunoglobulin light chain restriction in mantle cell lymphoma. (27125335)
2016
33
Modulation of p73 isoforms expression induces anti-proliferative and pro-apoptotic activity in mantle cell lymphoma independent of p53 status. (27074052)
2016
34
Diagnostic utility of SOX11 immunohistochemistry in differentiating cutaneous spread of mantle cell lymphoma from primary cutaneous B-cell lymphomas. (26762898)
2016
35
From Minimal Residual Disease to Maintenance Therapy: Optimizing Tools for Treatment of Mantle Cell Lymphoma. (27083467)
2016
36
Bortezomib for the treatment of mantle cell lymphoma: an update. (27493710)
2016
37
Pleomorphic mantle cell lymphoma morphologically mimicking diffuse large B-cell lymphoma: common cyclin D1 negativity and a simple immunohistochemical algorithm to avoid the diagnostic pitfall. (28032914)
2016
38
Diagnostic and therapeutic update of mantle cell lymphoma (MCL): analysis of seven cases treated in a centre in one year. (27110283)
2016
39
Ibrutinib-related atrial fibrillation in patients with mantle cell lymphoma. (27087288)
2016
40
CCND1-IGH Fusion-Amplification and MYC Copy Number Gain in a Case of Pleomorphic Variant Mantle Cell Lymphoma. (28028120)
2016
41
Deferred therapy is associated with improved overall survival in patients with newly diagnosed mantle cell lymphoma. (27153197)
2016
42
Pure red cell aplasia revealing nonnodal mantle cell lymphoma. (27322005)
2016
43
POINT: The Role of Stem Cell Transplantation in Mantle Cell Lymphoma. (27987196)
2016
44
Wells' syndrome with a clinicopathological correlation associated with mantle-cell lymphoma. (26999270)
2016
45
Endobronchial involvement of mantle cell lymphoma: A case report. (27536549)
2016
46
Multiple cutaneous metastases as the first sign of mantle cell lymphoma associated with multiple HPVA 52-positive squamous cell carcinomas of the skin. (27550714)
2016
47
Single-agent cytarabine is insufficient for the treatment of human mantle cell lymphoma in mouse xenograft model. (27468882)
2016
48
ZGDHu-1 promotes apoptosis of mantle cell lymphoma cells. (28035065)
2016
49
SOXC and MiR17-92 gene expression profiling defines two subgroups with different clinical outcome in mantle cell lymphoma. (26998831)
2016
50
Toll-Like Receptor 1/2 and 5 Ligands Enhance the Expression of Cyclin D1 and D3 and Induce Proliferation in Mantle Cell Lymphoma. (27123851)
2016

Variations for Mantle Cell Lymphoma

About this section

Cosmic variations for Mantle Cell Lymphoma:

8 (show top 50)    (show all 148)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1COSM3733281ANK2haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphomac.10807A>Gp.I3603V6
2COSM3733241CCND1haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphomac.160C>Tp.P54S6
3COSM44571TP53haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphomac.581T>Gp.L194R6
4COSM44972TP53haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphomac.831T>Ap.C277*6
5COSM22528ATMhaematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphomac.6011T>Gp.L2004R6
6COSM22518ATMhaematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphomac.484C>Tp.Q162*6
7COSM3733471KMT2Dhaematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphomac.7645C>Tp.Q2549*6
8COSM3733301SMARCA4haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphomac.2641G>Ap.D881N6
9COSM21642ATMhaematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphomac.9022C>Tp.R3008C6
10COSM3733378ATMhaematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphomac.6878T>Cp.L2293P6
11COSM3733326ANK2haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphomac.9148G>Tp.E3050*6
12COSM3733469EIF2AK4haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphomac.323C>Ap.S108Y6
13COSM379334NSD2haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphomac.3295G>Ap.E1099K6
14COSM10662TP53haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphomac.743G>Ap.R248Q6
15COSM3733438SMC1Ahaematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphomac.2400G>Tp.Q800H6
16COSM3733466ATP11Chaematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphomac.1703C>Ap.A568E6
17COSM1644312CCND1haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphomac.131A>Cp.Y44S6
18COSM3733368COL16A1haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphomac.385C>Ap.P129T6
19COSM6901TP53haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphomac.559+1G>Ap.?6
20COSM3733410COL11A1haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphomac.5008G>Cp.V1670L6
21COSM1739727ATMhaematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphomac.7343A>Cp.D2448A6
22COSM3733315ATMhaematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphomac.9007A>Gp.N3003D6
23COSM10667TP53haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphomac.646G>Ap.V216M6
24COSM3733492RB1haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphomac.1535T>Ap.L512*6
25COSM3733463ATP11Chaematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphomac.3044C>Gp.A1015G6
26COSM3733415NINhaematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphomac.806C>Gp.S269C6
27COSM3733443FAT4haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphomac.2098G>Ap.E700K6
28COSM3733318PLXNB3haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphomac.4099C>Tp.R1367C6
29COSM236699ATMhaematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphomac.6374A>Gp.H2125R6
30COSM3733306DHDHhaematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphomac.733G>Ap.G245S6
31COSM3733479NOTCH1haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphomac.4640A>Gp.Q1547R6
32COSM43826TP53haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphomac.706T>Ap.Y236N6
33COSM1312881KMT2Chaematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphomac.2758G>Tp.V920L6
34COSM11450TP53haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphomac.644G>Tp.S215I6
35COSM1644274CCND1haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphomac.130T>Gp.Y44D6
36COSM3733251ATMhaematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphomac.6126G>Ap.W2042*6
37COSM3733406KMT2Chaematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphomac.11879G>Ap.R3960Q6
38COSM3733302COL11A1haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphomac.1485T>Ap.D495E6
39COSM3733299EIF2AK4haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphomac.550G>Tp.E184*6
40COSM3733325ZNF296haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphomac.488G>Ap.G163D6
41COSM22497ATMhaematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphomac.3077+2T>Cp.?6
42COSM44962TP53haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphomac.774A>Tp.E258D6
43COSM10648TP53haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphomac.524G>Ap.R175H6
44COSM22514ATMhaematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphomac.8774G>Tp.G2925V6
45COSM3733455CDH8haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphomac.226G>Ap.G76R6
46COSM3733256ATMhaematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphomac.8631G>Cp.L2877F6
47COSM3733237CCND1haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphomac.106G>Cp.E36Q6
48COSM22506ATMhaematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphomac.7267G>Ap.E2423K6
49COSM3733500SMARCA4haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphomac.3565C>Gp.R1189G6
50COSM10749TP53haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphomac.830G>Tp.C277F6

Copy number variations for Mantle Cell Lymphoma from CNVD:

6 (show all 39)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
14497810660000012200000LossMantle cell lymphoma
24910311102900000110400000LossACATMantle cell lymphoma
34910411102900000110400000LossATMMantle cell lymphoma
44910511102900000110400000LossCUL5Mantle cell lymphoma
54910611102900000110400000LossFDX1Mantle cell lymphoma
64910711102900000110400000LossNPATMantle cell lymphoma
74910811102900000110400000LossRAB39Mantle cell lymphoma
84970311110400000112500000LossMantle cell lymphoma
94999011112500000114500000LossTMPRSS5Mantle cell lymphoma
104999111112500000114500000LossUSP28Mantle cell lymphoma
114999211112500000114500000LossZW10Mantle cell lymphoma
1254401114350000048800000LossTP53I11Mantle cell lymphoma
1360881119280000097200000LossMAML2Mantle cell lymphoma
14612621197200000102100000LossBIRC2Mantle cell lymphoma
15612631197200000102100000LossBIRC3Mantle cell lymphoma
167417613101700000104800000LossBIVMMantle cell lymphoma
177417713101700000104800000LossERCC5Mantle cell lymphoma
187417813101700000104800000LossKDELC1Mantle cell lymphoma
197469413110300000115169878LossC13orf11Mantle cell lymphoma
207469513110300000115169878LossC13orf17Mantle cell lymphoma
217469613110300000115169878LossCUL4AMantle cell lymphoma
227469713110300000115169878LossGRTP1Mantle cell lymphoma
23746983117011831117647068LossLAMPMantle cell lymphoma
247469913110300000115169878LossTFDP1Mantle cell lymphoma
2577990134887788349056026DeletionRB1Mantle cell lymphoma
2679883137900000095000000Copy numbermiR-17-92Mantle cell lymphoma
27809251399300000101700000LossPCCAMantle cell lymphoma
281181151775717207590868MutationP53Mantle cell lymphoma
291414322210288771210598834DeletionMAP2Mantle cell lymphoma
301435122237300000243199373LossMantle cell lymphoma
311708523160700000167600000LossSLITRK3Mantle cell lymphoma
322451729102600000108200000LossINVSMantle cell lymphoma
332488379137400000141213431LossTRAF2Mantle cell lymphoma
3425073492196775121994490DeletionCDKN2AMantle cell lymphoma
3525271493630000038400000LossMELKMantle cell lymphoma
3625474796870000072200000LossTJP2Mantle cell lymphoma
3725630999180000093900000LossDIRAS2Mantle cell lymphoma
38256992999300000102600000LossGPR51Mantle cell lymphoma
39256993999300000102600000LossTBC1D2Mantle cell lymphoma

Expression for genes affiliated with Mantle Cell Lymphoma

About this section
Search GEO for disease gene expression data for Mantle Cell Lymphoma.

Pathways for genes affiliated with Mantle Cell Lymphoma

About this section

Pathways related to Mantle Cell Lymphoma according to GeneCards Suite gene sharing:

(show top 50)    (show all 90)
idSuper pathwaysScoreTop Affiliating Genes
1
Show member pathways
10.1ATM, MDM2, TP53
2
Show member pathways
10.1ATM, MDM2, TP53
310.1CCND1, MDM2, TP53
410.1ATM, BCL2, MCL1
510.1BCL2, CCND1, MYC
610.1BCL2, CCND1, MYC
710.0ATM, MYC, TP53
810.0CCND1, MYC, TP53
910.0CCND1, MYC, TP53
1010.0CCND1, CCND2, MYC
1110.0CCND1, MTOR, MYC
1210.0MDM2, MYC, TP53
13
Show member pathways
10.0CCND1, CCND2, CCND3
1510.0MTOR, MYC, TP53
1610.0MTOR, MYC, TP53
17
Show member pathways
10.0BCL2, MCL1, PMAIP1
18
Show member pathways
10.0BCL2, MCL1, PMAIP1
1910.0BCL6, EZH2, MTOR
2010.0MCL1, PMAIP1, TP53
2110.0ATM, BCL2, MDM2, TP53
229.9CCND3, MTOR, MYC
23
Show member pathways
9.9ATM, MDM2, MTOR, TP53
249.9BCL2, CCND1, MCL1, TP53
259.9BCL2, CCND1, MYC, TP53
269.9ATM, CCND1, MTOR, MYC
27
Show member pathways
9.9CCND1, MDM2, MYC, TP53
28
Show member pathways
9.9CCND1, MDM2, MYC, TP53
299.9CCND1, CCND2, MYC, TP53
30
Show member pathways
9.9BCL2, BTK, CCND2, MYC
31
Show member pathways
9.8ATM, BCL2, CCND1, MDM2, TP53
329.8CCND1, CCND2, CCND3, MYC
339.8CCND1, CCND2, CCND3, MYC
34
Show member pathways
9.8CCND1, CCND2, CCND3, MYC
35
Show member pathways
9.8ATM, BCL6, PMAIP1, TP53
369.8ATM, CCND3, MCL1, MYC
379.8BCL2, MCL1, MYC, PMAIP1
38
Show member pathways
9.8ATM, CCND1, MDM2, MYC, TP53
39
Show member pathways
9.8ATM, BCL2, MDM2, MTOR, TP53
409.8BCL2, CCND1, MDM2, MTOR, TP53
419.8BCL2, BMI1, MDM2, MTOR, TP53
429.8ATM, BCL2, MDM2, MYC, TP53
439.8BCL6, CD19, CD5, MME
449.8ATM, BCL2, MDM2, PMAIP1, TP53
45
Show member pathways
9.8BCL6, BTK, CD19, MTOR
46
Show member pathways
9.8ATM, BCL6, CCND1, CCND2, MDM2
479.8ATM, CCND1, CCND2, CCND3, TP53
48
Show member pathways
9.8ATM, CCND1, CCND2, CCND3, TP53
49
Show member pathways
9.7BCL6, BTK, CD19, MYC
50
Show member pathways
9.7CCND1, MDM2, MTOR, MYC, TP53

GO Terms for genes affiliated with Mantle Cell Lymphoma

About this section

Cellular components related to Mantle Cell Lymphoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1cyclin-dependent protein kinase holoenzyme complexGO:000030710.9CCND1, CCND2, CCND3
2mitochondrial outer membraneGO:000574110.6BCL2, MCL1, MTOR, PMAIP1
3protein complexGO:00432349.7BCL2, CD19, MDM2, MYC, TP53
4nucleoplasmGO:00056549.3ATM, BCL2, BCL6, BMI1, CCND1, CCND2
5cytoplasmGO:00057379.1ATM, BCL2, BMI1, BTK, CCND1, CCND2
6nucleusGO:00056348.7ATM, BCL2, BCL6, BMI1, BTK, CCND1

Biological processes related to Mantle Cell Lymphoma according to GeneCards Suite gene sharing:

(show all 45)
idNameGO IDScoreTop Affiliating Genes
1determination of adult lifespanGO:000834011.0ATM, TP53
2mitotic G1 DNA damage checkpointGO:003157111.0CCND1, TP53
3cellular response to X-rayGO:007148111.0ATM, CCND2
4oocyte developmentGO:004859911.0ATM, BCL2
5cellular response to actinomycin DGO:007271711.0MDM2, TP53
6growthGO:004000711.0BCL2, MTOR
7positive regulation of DNA damage response, signal transduction by p53 class mediatorGO:004351710.9ATM, PMAIP1
8positive regulation of neuron maturationGO:001404210.9BCL2, MTOR
9re-entry into mitotic cell cycleGO:000032010.9CCND1, MYC
10cellular response to organic substanceGO:007131010.9BCL2, CCND1, MDM2
11cellular response to gamma radiationGO:007148010.9ATM, MDM2, TP53
12DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestGO:000697710.9ATM, MDM2, TP53
13positive regulation of glial cell proliferationGO:006025210.8MTOR, MYC
14liver regenerationGO:009742110.8CCND1, EZH2, MYC
15positive regulation of histone deacetylationGO:003106510.8BCL6, TP53
16cell agingGO:000756910.8BCL2, MTOR, TP53
17ovarian follicle developmentGO:000154110.8ATM, BCL2, MYC
18positive regulation of cell cycleGO:004578710.8CCND1, MDM2, MYC
19cellular response to glucose starvationGO:004214910.8BCL2, PMAIP1, TP53
20negative regulation of autophagyGO:001050710.8BCL2, MCL1, MTOR
21post-embryonic developmentGO:000979110.8ATM, BCL2, MTOR
22positive regulation of cyclin-dependent protein serine/threonine kinase activityGO:004573710.7CCND1, CCND2, CCND3
23positive regulation of intrinsic apoptotic signaling pathwayGO:200124410.7BCL2, PMAIP1, TP53
24positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathwayGO:190074010.7BCL2, PMAIP1, TP53
25negative regulation of gene expressionGO:001062910.7EZH2, MDM2, MYC, SOX11
26cell cycle arrestGO:000705010.7ATM, MTOR, MYC, TP53
27response to magnesium ionGO:003202610.6CCND1, MDM2
28replicative senescenceGO:009039910.6ATM, MME, TP53
29response to iron ionGO:001003910.6BCL2, CCND1, MDM2
30regulation of mitochondrial membrane permeabilityGO:004690210.5BCL2, PMAIP1, TP53
31positive regulation of protein phosphorylationGO:000193410.5CCND1, CCND2, CCND3, MTOR
32cell proliferationGO:000828310.5BCL2, CD5, MYC, SOX11, TP53
33response to gamma radiationGO:001033210.5BCL2, MYC, TP53
34regulation of cell cycleGO:005172610.4ATM, BCL2, CCND1, CCND2, CCND3
35positive regulation of gene expressionGO:001062810.4MDM2, MTOR, MYC, SOX11, TP53
36regulation of cell proliferationGO:004212710.4BCL6, BTK, CCND3, EZH2
37apoptotic processGO:000691510.4ATM, BCL2, BTK, MCL1, PMAIP1, TP53
38positive regulation of cell proliferationGO:000828410.4BCL2, CCND1, CCND2, MDM2, MYC, SOX11
39regulation of gene expressionGO:001046810.3BCL2, BMI1, EZH2, MDM2, MYC
40cellular response to hypoxiaGO:007145610.3BCL2, MDM2, MTOR, MYC, PMAIP1, TP53
41regulation of apoptotic processGO:004298110.2ATM, BCL2, BCL6, MCL1, PMAIP1, TP53
42cellular response to DNA damage stimulusGO:000697410.2ATM, BCL2, BCL6, CCND1, MYC, PMAIP1
43negative regulation of apoptotic processGO:004306610.1BCL2, BCL6, CCND2, MCL1, MDM2, MYC
44response to steroid hormoneGO:004854510.1BCL2, CCND1, MDM2
45negative regulation of transcription from RNA polymerase II promoterGO:00001229.9BCL6, BMI1, CCND1, CCND3, EZH2, MDM2

Molecular functions related to Mantle Cell Lymphoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1BH3 domain bindingGO:005143411.0BCL2, MCL1
2protein kinase bindingGO:00199019.7CCND1, CCND2, CCND3, MTOR, TP53
3protein bindingGO:00055158.3ATM, BCL2, BCL6, BMI1, BTK, CCND1

Sources for Mantle Cell Lymphoma

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet